How The Cardlytics (CDLX) Narrative Is Resetting After Guidance Changes And Partner Exits

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.

Cardlytics is back in focus after its latest fair value estimate was trimmed from US$1.29 to US$1.04, pointing to a lower price target in the updated analyst narrative. Much of this reset is being linked directly to Q4 results, Q1 guidance, and the revenue implications of the BofA exit and Bridg divestiture, which have pushed analysts to mark expectations closer to current realities. Reading on, you will see how bullish and bearish voices are framing these changes and how you can track the evolving story from here.

Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value Cardlytics.

What Wall Street Has Been Saying

🐂 Bullish Takeaways

Lake Street keeps a Hold rating while trimming its price target to US$1.25 from US$1.50, signaling that, in its view, the current reset already reflects the expected hit from the BofA exit and Bridg sale. Lake Street comments that Q1 guidance has “appropriately level set” expectations, which some investors may read as a cleaner starting point to judge future execution without legacy noise.

🐻 Bearish Takeaways

Evercore ISI cuts its price target to US$1 from US$2 and keeps an In Line rating, highlighting that the latest Q4 report and Q1 outlook have pulled fair value estimates lower. Lake Street describes the stock as still in “show me” territory, underscoring concerns about execution and the need for clearer proof that the business can offset the revenue hit from losing BofA and divesting Bridg.

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives!NasdaqGM:CDLX 1-Year Stock Price Chart

We've flagged 3 risks for Cardlytics. See which could impact your investment.

What's in the News

Cardlytics issued Q1 2026 revenue guidance of US$35.0 million to US$40.0 million, giving you a clear range to watch ahead of the next earnings report. The new guidance range sets out what management currently expects from the business over the near term, providing a direct reference point against recent analyst price target changes. For readers focused on liquidity and runway, this Q1 2026 outlook helps frame the upcoming earnings release as an important check on how actual revenue lines up with stated expectations.

How This Changes the Fair Value For Cardlytics

Fair value trimmed from US$1.29 to US$1.04, an approximate 18% reduction in the implied value per share. Revenue growth assumption revised from an 8.32% decline to a 13.01% decline. Net profit margin adjusted from 10.02% to 9.93%. Future P/E moved from 6.38x to 6.07x. Discount rate held steady at 12.33%.

Story Continues

Never Miss an Update: Follow The Narrative

Narratives link a company's business story to a financial forecast and fair value so you can see how assumptions, risks, and potential rewards fit together. They update automatically when analysts revise their views or new information comes through.

Head over to the Simply Wall St Community and follow the Narrative on Cardlytics to stay up to date on:

How expanding partnerships with financial institutions and non bank publishers, including the Cardlytics Rewards platform, shape user reach and operating scale. What increasing use of personalized, data driven marketing and first party, consent based purchase data could mean for advertiser loyalty and pricing power. Key risks such as partner content restrictions, advertiser churn, slower product investment, and reliance on debt that could pressure revenue and earnings.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include CDLX.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments